In cutaneous melanoma, where the use of circulating epigenetic biomarkers has been proposed as a non-invasive tool for tumor detection, promoter hypermethylation of RASSF1A has been described in plasma samples as a diagnostic indicator, with the ability of discriminating between melanoma patients and healthy individuals, showing a good diagnostic accuracy with an AUC of 0.90 [184]. Here, RASSF1 is linked to neoplasm.